Pulse Biosciences Schedules First Quarter 2021 Financial Results Conference Call for May 10, 2021
Pulse Biosciences, Inc. (Nasdaq: PLSE) is set to report its first-quarter 2021 financial results on May 10, 2021, post-market close. A conference call will follow at 1:30 PM PT, where management will discuss the financial outcomes. Interested investors can join by dialing the provided numbers or by accessing the webcast available on the company's investor relations website. Pulse Biosciences is dedicated to advancing its Nano-Pulse Stimulation™ (NPS™) technology, notably through its CellFX® System, which targets dermatologic conditions while ensuring non-thermal clearance of cells.
- Upcoming financial results report for Q1 2021 may provide insights into company performance.
- The CellFX System's unique NPS technology addresses unmet needs in dermatologic treatment.
- None.
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the first quarter of 2021 after market close on Monday, May 10, 2021. Company management will host a corresponding conference call beginning at 1:30pm PT.
Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. To learn more, please visit pulsebiosciences.com.
To stay informed about the CellFX System, please visit CellFX.com and sign up for updates.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005769/en/
FAQ
When will Pulse Biosciences report its financial results for Q1 2021?
What time is the conference call for Pulse Biosciences Q1 results?
How can investors listen to the Pulse Biosciences conference call?
What technology does Pulse Biosciences use in its CellFX System?
What dermatologic conditions does the CellFX System aim to treat?
